Evidence map›Paper›PMID 28049453›Full record

Trial reportBMC cancer2017

Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study.

Sally Jane O'Shea, Zoe Rogers, Fiona Warburton, Amanda J Ramirez, Julia A Newton-Bishop, Lindsay J L Forbes

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Delay in Seeking Medical Attention and Diagnosis in Chinese Melanoma Patients: A Cross-Sectional Study.International journal of environmental research and public health · 2022
    Article
  4. Article
  5. Yonder: Melanoma, child and family liaison, gastric bypass surgery, and QOF.The British journal of general practice : the journal of the Royal College of General Practitioners · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sally Jane O'SheaSection of Epidemiology and Biostatistics, Cancer Genetics Building, Leeds Institute of Cancer and Pathology, University of Leeds, St. James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK. S.J.O'Shea@leeds.ac.uk.
Zoe RogersSection of Epidemiology and Biostatistics, Cancer Genetics Building, Leeds Institute of Cancer and Pathology, University of Leeds, St. James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK.
Fiona WarburtonDivision of Cancer Studies, King's College London, Research Oncology, Guy's Hospital, Bermondsey Wing, 3rd Floor, Great Maze Pond, London, SE1 9RT, UK.
Amanda J RamirezDivision of Cancer Studies, King's College London, Research Oncology, Guy's Hospital, Bermondsey Wing, 3rd Floor, Great Maze Pond, London, SE1 9RT, UK.
Julia A Newton-BishopSection of Epidemiology and Biostatistics, Cancer Genetics Building, Leeds Institute of Cancer and Pathology, University of Leeds, St. James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK.
Lindsay J L ForbesDivision of Cancer Studies, King's College London, Research Oncology, Guy's Hospital, Bermondsey Wing, 3rd Floor, Great Maze Pond, London, SE1 9RT, UK.

Funding

Cancer Research UK 19167Cancer Research UK C37059/A17894Cancer Research UK C588/A19167
6 · The paper itself

Abstract

backgroundThe incidence of melanoma is rising. Early detection is associated with a more favourable outcome. The factors that influence the timing of a patient's presentation for medical assessment are not fully understood. The aims of the study were to measure the nature and duration of melanoma symptoms in a group of patients diagnosed with melanoma within the preceding 18 months and to identify the symptoms and barriers associated with a delay in presentation.

methodsA questionnaire was distributed to a random sample of 200 of the 963 melanoma patients who had participated in the Cancer Patient Experience Survey 2010 and were known to be alive 1 year later. Data were collected on symptoms, duration of symptoms prior to presentation and the reasons for not attending a doctor sooner.

resultsA total of 159 patients responded to the questionnaire; 74 (47%) were men; mean age was 62 (range 24-90) years. Of the 149 patients who reported a symptom, 40 (27%) had a delayed presentation (i.e. >3 months). A mole growing bigger was the most common symptom and reporting this symptom was significantly associated with a delayed presentation (odds ratio (OR) 2.04, 95% confidence interval (95% CI) 1.14-5.08). Patients aged ≥65 years were less likely to report a barrier to presentation and were less likely to delay than those under 40, although this was of borderline statistical significance (OR 0.28, 95% CI 0.08-1.00).

conclusionsThis study highlights that an enlarging mole is a significant symptom influencing the timing of presentation. Increasing public awareness of the signs of melanoma and of the importance of early presentation is desirable. Health professionals should take advantage of the opportunity to educate patients on such symptoms and signs where feasible. Further exploration of the barriers to presentation in younger people should be considered.

Indexed as

Delayed DiagnosisHealth Knowledge, Attitudes, PracticeAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansIncidenceMaleMelanomaMiddle AgedPatient Acceptance of Health CarePrognosisRetrospective StudiesRisk FactorsBehavioural symptomsDelayed diagnosisMelanoma

Identifiers

PMID28049453
PMCPMC5209829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.